Yong Liu

This inventor holds 27 USPTO granted patents and 8 published patent applications, plus 15 CIPO patents and 8 EPO patents, primarily in Kinase Inhibitors. Top assignees: University Health Network, Propellon Therapeutics Inc., University of Toronto. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yong Liu. Retrieved from https://idiyas.com/inventor/yong-liu-ijulcpsd

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 8)

% Patents Active = 88.9

CIPO Patents = 15 (Patent Applications = 8)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 8.6

ph-index = 9

Forward Citations = 163(Granted Patents)

Location History:

Toronto, CA (2014)
North York, CA (2012 - 2015)
Oakville, CA (2014 - 2022)

Company Filing History:

22 out of 312

University Health Network

patents

3 out of 3

Propellon Therapeutics Inc.

patents

1 out of 530

University of Toronto

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Isoindolinone Compounds

Aminopyrimidine

WDR5 Inhibitors

HPK1 Inhibitors

Pyrazolopyrimidine

Chiral Synthesis

Indazole Compounds

Carnitine Palmitoyltransferase

Protein-Protein Binding

Cancer Treatment

Cancer Inhibitors

Substituted Carboxamides

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12643886 - Isoindolinone aminopyrimidine compounds as inhibitors of NUAK kinases, compositions and uses thereof (2026-06-02),

2. 12264147 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2025-04-01),

3. 11319299 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2022-05-03),

4. 11174250 - Substituted carboxamides as inhibitors of WDR5 protein-protein binding (2021-11-16),

5. 11059832 - HPK1 inhibitors and methods of using same (2021-07-13),

6. 10570143 - Pyrazolopyrimidine compounds (2020-02-25),

7. 10501474 - HPK1 inhibitors and methods of using same (2019-12-10),

8. RE47731 - Kinase inhibitors and method of treating cancer with same (2019-11-18),

9. 10358436 - Kinase inhibitors and method of treating cancer (2019-07-23),

10. 10167289 - Pyrazolopyrimidine compounds (2019-01-01),

11. 10106545 - Pyrazolopyrimidine compounds (2018-10-23),

12. 10077255 - Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2′-ones (2018-09-18),

13. 9907800 - Kinase inhibitors and method of treating cancer (2018-03-06),

14. 9796703 - Synthesis of chiral 2-(1H-indazol-6-yl)-spiro[cyclopropane-1,3'-indolin]-2′-ones (2017-10-24),

15. 9657025 - Pyrazolopyrimidine compounds (2017-05-23),

Title: The Innovative Journey of Yong Liu

Introduction: Yong Liu, a visionary inventor hailing from Oakville, CA, has made significant contributions to the field of technology with his groundbreaking innovations.

Latest Patents: Yong Liu's latest patents include a cutting-edge artificial intelligence algorithm for predictive analytics and a revolutionary wearable device for monitoring vital signs in real-time.

Career Highlights: With a career spanning over two decades, Yong Liu has established himself as a pioneer in the tech industry. He has held key positions in leading tech companies, where he spearheaded research and development projects that have shaped the future of technology.

Collaborations: Yong Liu has collaborated with top research institutions and universities to further his innovative projects. His partnerships have led to the development of cutting-edge technologies that have been recognized globally.

Conclusion: Yong Liu's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors. His impact on the tech industry is profound, and his legacy is sure to endure for years to come.

Profile summary based on public USPTO records.